Translational relevance: The combination of fludarabine, cyclophosphamide, and rituximab is now standard therapy for most previously untreated chronic lymphocytic leukemia (CLL). However, it was remarkable that patients who failed to maintain a response to this therapy subsequently responded to a phase 1-2 trial of oxaliplatinbased therapy that also included fludarabine We hypothesized that the mechanism of action for this combination was dependent on the ability of cells to excise the oxaliplatin 
Translational relevance: The combination of fludarabine, cyclophosphamide, and rituximab is now standard therapy for most previously untreated chronic lymphocytic leukemia (CLL). However, it was remarkable that patients who failed to maintain a response to this therapy subsequently responded to a phase 1-2 trial of oxaliplatinbased therapy that also included fludarabine We hypothesized that the mechanism of action for this combination was dependent on the ability of cells to excise the oxaliplatin adduct and initiate DNA-repair synthesis. Experiments that examined the fludarabineoxaliplatin interactions demonstrated synergistic killing of CLL cells that was dependent on the activity of the nucleotide excision repair endonuclease, XPF. Fludarabine blocked XPF-dependent DNA re-synthesis in this repair mechanism. Treatment of CLL cells with the combination also caused accumulation of DNA damage, and initiated DNA repair signaling followed by activation of apoptotic pathways. This understanding of the mechanistic interaction of fludarabine and oxaliplatin predicts that this combination may be equally, if not more, effective than the current standard of care. This suggests
Introduction
Introduction of fludarabine and other purine nucleoside analogs in the treatment of chronic lymphocytic leukemia (CLL) generated a significant improvement in patient response (1). These proved more effective than the use of alkylating agents alone (2) (3) (4) . Fludarabine is incorporated into the DNA by DNA polymerases, inhibiting replication (5) . The incorporated analog is not a substrate for ligation, (6) and attempts of DNA polymerase ε to excise it inactivates the polymerase (7) . The great majority of CLL cells are not cycling, thus fludarabine incorporation into DNA is at a low level, likely representing endogenous repair synthesis (8) .
Induction of excision repair of DNA damage is a potential mechanism to increase fludarabine incorporation. Irradiation with ultraviolet light, which induces nucleotide excision repair (NER), led to the dose-dependent incorporation of fludarabine into the DNA of quiescent lymphocytes and inhibition of 60-70% of repair (9, 10) Similar results were observed in response to fludarabine or clofarabine and cyclophosphamide in CLL cells (11) . The greater than additive killing of cells provided rationale for the design of combinations in clinical trials. Subsequently, the clinical activity of combinations of these two classes of drugs, in particular fludarabine and cyclophosphamide, were proved superior to single agent fludarabine (12) (13) (14) . Recently, strategies to include antibody therapy have given substantial increases in the complete response rate for CLL patients (14) (15) (16) (17) (18) (19) and an indication of increased overall survival in response to fludarabine-cytoxan-rituximab therapy (20) . Nevertheless, relapses remain problematic and development of drug resistance continues to be a major challenge in CLL treatment (19) suggesting the need for new effective drugs. Although active, the toxicity of combinations of fludarabine with cisplatin with or without cytarabine has limited further clinical investigations (21, 22) . Oxaliplatin is a third generation platinum compound. It has a different toxicity profile from cisplatin and it induces distinct cell responses from its predecessor (23, 24) . Oxaliplatin forms a variety of DNA-crosslinks as well as monoadducts (25) (26) (27) , which are excised by NER (28) . Components of NER sense bulky adducts or distortions in the DNA helix (29) and recruit helicases which unwind the region around the adduct. This process allows the endonucleases XPF-ERCC1 and XPG to make incisions 5' and 3' of the adduct, respectively (30, 31) . Subsequently, the single-stranded 27-29 nucleotide oligomer with the adduct is removed during the gap-filling re-synthesis of DNA (32, 33) . This resynthesis provides an opportunity for incorporation of fludarabine nucleotide, which terminates further re-synthesis, an action that presumably leaves a single-stranded gap in the DNA repair patch (34) . The observations that oxaliplatin with fludarabine elicit greater than additive killing of CLL cells in vitro (27) provided the rationale for inclusion of this combination as a part of a phase I/II clinical trail in relapsed/refractory CLL (35) in which oxaliplatin might serve as the initiator of DNA repair and synthesis. The level of cytarabine in this combination treatment has been recently reduced to minimize myelosuppression (36) . The therapy retained its effectiveness suggesting that the combination could be successful without the need for a secondary analogue.
In seeking a mechanistic explanation for this activity, we hypothesized that effect of the fludarabine and oxaliplatin combination. We conclude from this work that nucleotide excision repair of oxaliplatin DNA adducts is essential for the mechanism of action of the fludarabine and oxaliplatin chemotherapeutic combination.
Materials and methods
Isolation of CLL cells. CLL samples used were from patients who signed a written informed consent to participate in the laboratory protocol, which was approved by the Immunoblot. Cells were lysed in ice-cold lysis buffer (50 mM Tris pH 8, 250 mM NaCl, 1% NP40, 0.1% SDS, 5 mM EDTA, 2 mM Na 3 VO 4 , 10 mM Na 2 P 2 O 7 , 10 mM NaF)
Research. Colony formation. Chinese hamster ovarian (CHO) cell lines, AA8 (wild-type) and its derivatives UV41 (XPF deficient) and UV135 (XPG deficient) were purchased from ATCC and authenticated by their sensitivity to UV and by cytogenetic analysis. Due to higher sensitivity of UV41 and UV135 to oxaliplatin ( Supplementary Fig. S1 ) the cells were exposed to equitoxic doses (AA8 5 μM; UV41 0.05 μM; UV135 0.5 μM). The cell line passage numbers ranged from 8 to 14. Cells were seeded at density of 400 cells per well, on six well dishes. Cells were allowed to attach overnight, then incubated with 0.5% FBS (Atlanta Biologicals) MEM media (Mediatech) for 24 hours, followed by exposure to specified concentrations. After treatment, samples were washed once with PBS and 10% FBS supplemented MEM alpha media was added. 10 days postexposure cells were fixed with 100% methanol and stained with Giemsa.
Statistical analysis: Analysis of Table 1 was done using ANOVA. The analysis of the figures was done using the paired student T-test. Analysis of the combinational effect for oxaliplatin and fludarabine exposure (Fig. 1A ) was done using CalcuSyn (Biosoft, Cambridge, UK), based on the median-effect method created by Chou and Talalay (38) .
Calculated combination index <1 indicates synergistic, =1 additive and >1 antagonistic relationship between agents.
Results
To understand the mechanism of fludarabine and oxaliplatin activity in CLL cells, we compared the cytotoxicity that the two drugs produce alone and in combination in twenty CLL samples. Clinical characteristics of the samples used in this study can be found in the Supplementary Table S1 . Preliminary investigations demonstrated that a Table S2 ). Thus, these minimally toxic concentrations, which are clinically achievable, induced greater than additive cell killing in combination.
Synergy between two drugs is best observed upon the analysis of a wide dose range for both drugs alone and in combination. The dose range tested for our studies was 0.5-17 μM. Analysis of cell survival using CalcuSyn demonstrated the combination index for oxaliplatin and fludarabine to be less than 1 (Fig. 1A) , signifying synergism in CLL cells by the combination.
Because CLL cells have low replicative capacity, the combination strategy postulates that excision of oxaliplatin adducts by NER would provide an opportunity for the incorporation of fludarabine into the DNA repair patch. As a measure of this process, CLL cells were first incubated with oxaliplatin alone; pulses with [ of excision repair that in combination with fludarabine was adequate to induce greater than additive cell death (Table 1) .
The working hypothesis states that the mechanism of fludarabine and oxaliplatin combination is dependent on the excision of oxaliplatin adducts by NER. XPF endonuclease incises 5' of the DNA-adduct and is an essential component of the NER process. CLL cells were incubated with scrambled or XPF siRNA to create a CLL model of NER deficiency ( Supplementary Fig. S2 ). In samples incubated with scrambled siRNA, oxaliplatin induced a three-fold increase in thymidine incorporation at 8 hours ( (Fig. 1C, right panel) . These results are consistent with the hypothesis that the thymidine incorporation after oxaliplatin is a consequence of NER-mediated excision repair of DNA adducts. Fig. 1C suggested that NER is essential for synergistic activity of fludarabine and oxaliplatin. Unfortunately, the toxicity of the electroporation procedure limited the usefulness of CLL cell survival assays. Therefore, we examined the Chinese hamster ovary (CHO) cell culture model of XPF deficiency with equitoxic doses of oxaliplatin and fludarabine. The observed survival for wild-type AA8 cells was only 21%, which was significantly less than predicted (50%, p<0.01) confirming that the combination of the two agents results in greater-than-additive cell death (Fig. 1D) . In contrast, survival of XPF mutant UV41 cells was 54%, which was not significantly different from the predicted survival of 56%. A second AA8 cell line derivative, UV135, 
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lacks XPG activity, the NER endonuclease that incises 3' of the lesion. The predicted additive survival of UV135 cells after combination treatment was 52% and the observed survival was 31% (Fig. 1D) . Thus, NER is needed for the greater than additive killing by the combination, but the contribution of XPF is more substantial than that of XPG.
Blocked DNA synthesis likely results in incomplete repair due to termination of the re-synthesis step caused by the mis-incorporation of fludarabine triphosphate. This generates gaps in the DNA that could be detectable by the comet assay ( Fig. 2A) . Preincubation of samples in an alkaline solution (pH>12) prior to electrophoresis unwinds the DNA and allows detection of single-and double-strand breaks. The exposure of samples to both fludarabine and oxaliplatin resulted in a 4-fold increase of the Olive tail moment (OTM) compared to the time-matched controls at 24 hours and when compared with either agent alone (Fig. 2B, p=0 .03). Neutral comet assay was used to detect double-strand breaks. Analysis of four samples demonstrated that, while there was a tendency for an increase in the OTM after the combination, this increase was not statistically significant (Fig. 2C) . Thus, the generation of single-strand breaks supports the hypothesized mechanism for the interaction of fludarabine and oxaliplatin in CLL cell population.
The presence of DNA damage activates DNA-repair and signaling complexes that can be detected by phosphorylation of key proteins. DNA-PKcs and ATM are essential components of the non-homologous end-joining and homologous recombination pathways, respectively, and both are involved in repair of DNA doublestrand breaks. SMC1 is part of the chromatid cohesion complex; it is phosphorylated at Ser966 in response to DNA damage (39) . Phosphorylation of histone H2AX at Ser139
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is a well studied marker of DNA double-strand breaks and stalled replication forks (40) .
DNA-PKcs has a low background level of Ser2056 phosphorylation in CLL samples (Fig. 3A) and exposure to the combination increases its phosphorylation by 7-and 8-fold at 12 and 24 hours (Fig. 3B) . Phosphorylation of ATM at Ser1981 was less than DNA-PKcs, increasing 3-to 6-fold at the same times (Fig. 3C) . In comparison, the samples showed earlier phosphorylation of SMC1 at 4 and 6 hours post-exposure (Fig.   3D ). While the fold increase varied 6-to 20-fold among samples at 6 hours, its timecourse was consistent, initiated at 4 hours post-combination, peaking at 6 and 12 hours and tapering off by 24. Fludarabine also induced an increase in SMC1 phosphorylation but this appeared later than with the combination (12 and 24 hours, Fig. 3D ). Drug coexposure resulted in 10-fold increase of γ-H2AX at 12 hours (Fig. 3E ) and similarly to SMC1, γ-H2AX tapered off by 24 hours (4-fold increase over control). Taken together, the increase in phosphorylation of DNA damage response molecules is consistent with the conclusions that fludarabine and oxaliplatin combination causes greater than additive DNA damage.
Phosphorylation of DNA-PKcs and ATM suggested that the two molecules could be participating in repair of DNA damage caused by the drug combination. In order to assess whether this is the case, samples were pre-incubated with specific inhibitors of ATM or DNA-PKcs (Fig. 4) . Each kinase inhibitor blocked the auto-phosphorylation of the respective target protein after 5 Gy of IR (Fig. 4A) ; the DNA-PKcs inhibitor also decreased cell survival after IR (Fig. 4B) . The samples were incubated with inhibitors and the combination in order to test the contribution of ATM or DNA-PKcs to the repair of the resulting DNA damage. The cell survival response was independent of the Research.
on July 14, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from kinase inhibitor treatment in 4 samples tested (Fig. 4C) . Thus, while ATM and DNAPKcs are phosphorylated in response to the combination treatment, it does not appear that the DNA repair processes they mediate contribute substantially to viability of CLL cells.
We investigated signaling pathways that may be involved in the mechanisms of cell death after fludarabine and oxaliplatin exposure. An increase in p53 levels at 6, 12 and 24 hours paralleled the generation of single-strand breaks (Fig. 5A) . Analysis of 5 samples showed a general trend for time-dependent increase in p53 levels after exposure to the combination (Fig. 5B, left panel) . Expression of PUMA, the proapoptotic p53 target protein increased at 12 and 24 hours, although PUMA levels were also induced by fludarabine exposure at 12 hours (Fig. 5A) , demonstrating the ability of fludarabine to induce apoptotic signaling alone or in combination. PUMA levels correlated significantly with p53 stabilization (Fig. 5B, right Mediator caspases-8 and -9 activate the extrinsic and intrinsic apoptotic pathways, respectively. TRAIL treated U25 cells died through activation of the extrinsic mechanisms as can be seen by the cleavage of caspase-8 (Fig. 5E ). CLL cells showed low levels of caspase-8 and no detectable cleavage with either fludarabine treatment alone or fludarabine and oxaliplatin in combination (Fig. 5E ). Caspase-9 is responsible for the activation of the intrinsic apoptotic pathway. The combination increased the cleavage of caspase-9 5-fold over controls as opposed to fludarabine alone (2-fold) at 24 hours (Fig. 5E ). Taken together, the results presented here support the conclusion that the fludarabine and oxaliplatin-induced DNA damage activates both extrinsic and intrinsic pathways of CLL cell death.
Discussion
Combinations of nucleoside analogues and alkylating agents in CLL treatment were hypothesized to act by the induction of NER, followed by the incorporation of the nucleoside analog into DNA during the re-synthesis of the repair patch (11, 35) . It was reasoned that this would block completion of the repair process and induce signaling for cell death (27, 41) . As a test of this postulate, knockdown of XPF in CLL cells blocked Fig 1A) . NER is responsible for the removal of oxaliplatin mono-adducts from the DNA (42) and the XPF-ERCC1 complex is an essential part this pathway (32) . Cells lacking XPF endonuclease are 100-fold more sensitive to platinum than the wild-type cells (43) 
incubation necessary to achieve an efficient knockdown rendered the siRNA technique unusable in determining CLL cell death. Therefore, CHO cells with a wild-type and XPF or XPG mutant background were exposed to single agents or the combination. Colony formation assays confirmed that in a wild-type background, cells were more sensitive to combination exposure as opposed to either oxaliplatin or fludarabine alone. Cells with mutant XPF and XPG were exposed to 100-and 10-fold lower concentrations of oxaliplatin, respectively, to achieve comparable survival response. Without XPF, the effect of oxaliplatin and fludarabine exposure was only additive, suggesting that the mechanistic-based interaction between the two agents requires proficient excision of oxaliplatin adducts. In contrast, XPG deficient cells showed survival similar to their wildtype counterparts, signifying that even without XPG, cells are capable of initiating DNA synthesis as a response to oxaliplatin adducts.
There is evidence that XPF is capable of incisions on both 5' and 3' sides of the adduct, as is the case with branched oligonucleotides containing a (psoralen) crosslink (44, 45) . If XPF has the 3' endonuclease activity in vivo, it might substitute for XPG. If Inhibtion of both DNA-repair kinases produced no effect on cell killing after combination 
